Nevro Corp at JPMorgan Healthcare Conference Transcript
Good afternoon, everyone. I'm Robbie Marcus, the med tech analyst at JPMorgan. Thanks for joining. Happy to introduce our next session with Nevro. And the speaker is Chairman, CEO and President, Keith Grossman. Keith, I'll turn it over to you, and then we'll do a little Q&A.
Okay. Thank you, Robbie. Good afternoon, everyone. Thanks for joining us here in the room and for those of you who've joined us online. So we will -- here we go. We'll make some forward-looking statements, and we'll talk a little bit about some non-GAAP versus GAAP financial metrics. And I would refer you back to our SEC disclosures and safe harbor.
Okay. So let's talk a little bit about -- here we are in January at JPMorgan. Let's talk a little bit about how we exited 2022 and how we think we're coming into 2023. First of all, we grew in '22 in the quarter and for the full year in a market where that wasn't as easy to do as it
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
